Stockreport

Aviragen Adjourns Special Meeting of Stockholders to Allow Stockholders to Consider Improved Merger Deal Terms

Atea Pharmaceuticals, Inc. - common stock  (AVIR) 
PDF CAS Group Supports Improved DealCompany Currently has Sufficient Votes to Approve Merger ATLANTA, Feb. 09, 2018 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDA [Read more]